INVRAGEN (INV-DEN-203)

A double-blind, randomized, placebo-controlled, age descending and expansion Phase 2 study to investigate the safety and immunogenicity of a tetravalent chimeric dengue vaccine in healthy volunteers between the ages of 1.5–45 years.